Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak, et al.
The Lancet (2024) Vol. 403, Iss. 10427, pp. 632-644
Closed Access | Times Cited: 217

Showing 1-25 of 217 citing articles:

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Christian U Blank, Minke W Lucas, Richard A. Scolyer, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 18, pp. 1696-1708
Closed Access | Times Cited: 96
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Josep M. Llovet, Roser Pinyol, Mark Yarchoan, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 294-311
Closed Access | Times Cited: 87
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
Mark Yarchoan, Edward Gane, Thomas U. Marron, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1044-1053
Open Access | Times Cited: 51
Cancer mRNA vaccines: clinical advances and future opportunities
Elias Sayour, David Boczkowski, Duane A. Mitchell, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 489-500
Closed Access | Times Cited: 34
Cold and hot tumors: from molecular mechanisms to targeted therapy
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 26
Malignant Melanoma: An Overview, New Perspectives, and Vitamin D Signaling
Radomir M. Slominski, Tae‐Kang Kim, Zorica Janjetović, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2262-2262
Open Access | Times Cited: 15
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Justin F. Gainor, Manish R. Patel, Jeffrey S. Weber, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2209-2223
Closed Access | Times Cited: 15
Clinical advances of mRNA vaccines for cancer immunotherapy
Alexey V. Yaremenko, Muhammad Muzamil Khan, Xueyan Zhen, et al.
Med (2025) Vol. 6, Iss. 1, pp. 100562-100562
Closed Access | Times Cited: 4
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
Man Wang, Fei Yu, Yuan Zhang
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Juanita Lopez, Thomas Powles, Fadi Braiteh, et al.
Nature Medicine (2025) Vol. 31, Iss. 1, pp. 152-164
Open Access | Times Cited: 1
A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib
Huaxiang Wang, Junjun Li, Xiuling Zhu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Leveraging mRNA technology for antigen based immuno-oncology therapies
Charalampos S. Floudas, Siranush Sarkizova, Michele Ceccarelli, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010569-e010569
Open Access | Times Cited: 1
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
David A. Braun, Giorgia Moranzoni, Vipheaviny Chea, et al.
Nature (2025)
Open Access | Times Cited: 1
Fluorinated Organic Polymers for Cancer Drug Delivery
Jingrui Xin, Xue Lu, Ji-Min Cao, et al.
Advanced Materials (2024) Vol. 36, Iss. 30
Closed Access | Times Cited: 13
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy
Hussein Sultan, Yoshiko Takeuchi, Jeffrey P. Ward, et al.
Nature (2024) Vol. 632, Iss. 8023, pp. 182-191
Open Access | Times Cited: 13
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, et al.
European Journal of Cancer (2024) Vol. 211, pp. 114327-114327
Closed Access | Times Cited: 12
RNA vaccines for cancer: Principles to practice
Pablo Guasp, Charlotte Reiche, Zachary Sethna, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1163-1184
Closed Access | Times Cited: 10
Tumour mutational burden: clinical utility, challenges and emerging improvements
Jan Budczies, Daniel Kazdal, Michael Menzel, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 10, pp. 725-742
Closed Access | Times Cited: 10
Transforming vaccinology
Rino Rappuoli, Galit Alter, Bali Pulendran
Cell (2024) Vol. 187, Iss. 19, pp. 5171-5194
Closed Access | Times Cited: 10
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Ankita Mitra, Anoop Kumar, Nitin Amdare, et al.
Biology (2024) Vol. 13, Iss. 5, pp. 307-307
Open Access | Times Cited: 8
Development of mRNA Lipid Nanoparticles: Targeting and Therapeutic Aspects
Yaping Liu, Yingying Huang, Guantao He, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10166-10166
Open Access | Times Cited: 8
State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers
Scott Strum, Mads Hald Andersen, Inge Marie Svane, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 7
How personalized cancer vaccines could keep tumours from coming back
Elie Dolgin
Nature (2024) Vol. 630, Iss. 8016, pp. 290-292
Open Access | Times Cited: 7
Nucleic acid drugs: recent progress and future perspectives
Xiaoyi Sun, Sarra Setrerrahmane, Chencheng Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
Joline Ingels, Laurenz De Cock, Dieter Stevens, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 5, pp. 101516-101516
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top